ライフサイエンスコーパス: pulmonary embolism

1 e) and two PCC related (ischaemic stroke and pulmonary embolism).

2 isk of VTE events (deep venous thrombosis or pulmonary embolism).

3 onfirmed symptomatic deep vein thrombosis or pulmonary embolism).

4 ve accuracy of 0.90 (95% CIs: 0.78-1.00) for pulmonary embolism.

5 interval [CI], 0.04 to 1.2); no patient had pulmonary embolism.

6 Seventeen of the 105 patients (16.2%) had a pulmonary embolism.

7 ography was not indicated to safely rule out pulmonary embolism.

8 of origin of human DVT associated with fatal pulmonary embolism.

9 fibrillation and those at risk of recurrent pulmonary embolism.

10 cannula-associated deep vein thrombosis and pulmonary embolism.

11 lar size and function in patients with acute pulmonary embolism.

12 lasmin, may have unique therapeutic value in pulmonary embolism.

13 ciated with certain causes of arrest such as pulmonary embolism.

14 ombosis can lead to deep-vein thrombosis and pulmonary embolism.

15 as no evidence of an effect of statin use on pulmonary embolism.

16 sis, device migration, caval penetration, or pulmonary embolism.

17 osing right ventricular dysfunction in acute pulmonary embolism.

18 Adult in/outpatients diagnosed with acute pulmonary embolism.

19 eeding were examined in a humanized model of pulmonary embolism.

20 esuscitation is particularly associated with pulmonary embolism.

21 tical care physicians in patients with acute pulmonary embolism.

22 ating right ventricular dysfunction in acute pulmonary embolism.

23 ected thrombolysis for submassive or massive pulmonary embolism.

24 d, deep-vein thrombosis in the arm or leg or pulmonary embolism.

25 nfarction, stroke, deep vein thrombosis, and pulmonary embolism.

26 alysis focuses on the included patients with pulmonary embolism.

27 with severe disease, have increased risk of pulmonary embolism.

28 er use did not reduce the risk of subsequent pulmonary embolism.

29 3319 patients had pulmonary embolism.

30 lar diameter ratio in massive and submassive pulmonary embolism.

31 d to identify and treat patients at risk for pulmonary embolism.

32 pulmonary arterial system is referred to as pulmonary embolism.

33 al stemming from incompletely resolved acute pulmonary embolism.

34 ry angiography was performed to evaluate for pulmonary embolism.

35 ctor for deep vein thrombosis of the leg and pulmonary embolism.

36 ment of the pulmonary trunk to investigate a pulmonary embolism.

37 ired infections, venous thromboembolism, and pulmonary embolism.

38 oice for preventing deep vein thrombosis and pulmonary embolism.

39 Of 794 scans, 78 (9.8%) were positive for pulmonary embolism.

40 with and without contrast media to rule out pulmonary embolism.

41 the emergency department for suspected acute pulmonary embolism.

42 e outcomes in UK BioBank, most strongly with pulmonary embolism.

43 ng and does not suggest routine use in acute pulmonary embolism.

44 m the emergency department to rule out acute pulmonary embolism.

45 ary vasodilation in a porcine model of acute pulmonary embolism.

46 to approximate 2.3% among survivors of acute pulmonary embolism.

47 unprovoked events, deep vein thrombosis, and pulmonary embolism.

48 of pyrexia, cardiogenic pulmonary edema and pulmonary embolisms.

49 r extremity thrombosis (0.77% versus 0.96%), pulmonary embolism (0.38% versus 0.96%), or urgent surge

50 cluding 1 patient who died (relative risk of pulmonary embolism, 0; 95% CI, 0.00 to 0.55).

51 2.22, 95% CrI 1.78-2.89, p<0.0001) and fatal pulmonary embolism (1.58, 1.14-2.19, p=0.01), but less m

52 at least 5% of patients in either group was pulmonary embolism (13 [6%] vs seven [3%]).

53 yed fixation suffered 2-fold higher rates of pulmonary embolism (2.6% versus 1.3%; rate ratio [RR] 2.

54 is was associated with a lower occurrence of pulmonary embolism (2/18; 11%) than standard regimen (11

55 d possibly or probably related to treatment (pulmonary embolism [200 mg/day], respiratory failure [12

56 ith COVID-19 have an increased prevalence of pulmonary embolisms (26%), and most (78.7%) have moderat

57 Six patients with pulmonary embolism (46%) and 14 patients without pulmona

58 1 minutes, P = 0.001), and increased rate of pulmonary embolism (5.4% vs 0.9%, P = 0.007) in comparis

59 onary embolism (46%) and 14 patients without pulmonary embolism (52%) died at ICU discharge (odds rat

60 public awareness is substantially lower for pulmonary embolism (54%) and deep-vein thrombosis (44%)

61 Thrombolysis Procedure for Intermediate-Risk Pulmonary Embolism; 8 mg/2 hours, 8 mg/4 hours, 12 mg/6

62 endpoint of this study was the occurrence of pulmonary embolism according to the use of standard thro

63 950 921; among individuals aged 15-55 years, pulmonary embolism accounted for 8-13 per 1000 deaths in

64 for the treatment of critical limb ischemia, pulmonary embolism, acute ischemic stroke, and acute aor

65 onary complications including development of pulmonary embolism, acute respiratory distress syndrome,

66 he occurrence of deep vein thrombosis alone, pulmonary embolism alone.

67 Both scores successfully exclude pulmonary embolism, although YEARS has a better negative

68 The prevalence of pulmonary embolism among patients hospitalized for synco

69 modynamics were evaluated at baseline, after pulmonary embolism and after each dose by biventricular

70 ts were evaluated in vivo at baseline, after pulmonary embolism and after each dose by invasive hemod

71 Eligible patients had submassive or massive pulmonary embolism and an RV/LV diameter ratio >=0.9 on

72 ll-established risk factor for VTEs, such as pulmonary embolism and deep vein thrombosis.

73 Venous thromboembolism (VTE), composed of pulmonary embolism and deep venous thrombosis, is a sign

74 s thromboembolism (which comprised events of pulmonary embolism and deep-vein thrombosis) was more co

75 rent venous thromboembolism in patients with pulmonary embolism and evidence of right ventricular dys

76 Two dose-limiting toxicities (grade 2 pulmonary embolism and grade 4 hypocellular marrow) occu

77 08 [95% CrI 0.00-1.76]), but the results for pulmonary embolism and major bleeding are highly uncerta

78 The results of the pulmonary embolism and major bleeding meta-analyses are

79 us adverse events occurred during the study (pulmonary embolism and myocarditis while taking amantadi

80 ion of a low pretest clinical probability of pulmonary embolism and negative d-dimer assay.

81 the eltrombopag group: one treatment-related pulmonary embolism and one vertigo.

82 common were at significantly greater risk of pulmonary embolism and required longer hospital stay.

83 nd readily available, the rapid diagnosis of pulmonary embolism and use of thrombolytics during cardi

84 dilation in a porcine in vivo model of acute pulmonary embolism and vasorelaxation in isolated pulmon

85 The location of pulmonary embolisms and the degree of elevation of D-dim

86 large intestine perforation, pneumonia, and pulmonary embolism) and two (1%) in the lenalidomide and

87 y heart disease, invasive breast cancer, and pulmonary embolism), and raloxifene (venous thromboembol

88 ents are hemodynamically unstable with acute pulmonary embolism, and a minority of them have proximal

89 ished VTE risk factors), and unprovoked VTE, pulmonary embolism, and deep-vein thrombosis.

90 mary endpoint, and pulmonary embolism, fatal pulmonary embolism, and major bleeding as secondary endp

91 n thrombosis (symptomatic and asymptomatic), pulmonary embolism, and major bleeding.

92 tion, thyrotoxicosis, alcohol, pericarditis, pulmonary embolism, and myocarditis).

93 ictegravir group and one unknown causes, one pulmonary embolism, and one lymphoma in the dolutegravir

94 hrombosis, two patients (15.4%) had isolated pulmonary embolism, and one patient (7.7%) had both cann

95 ficiency or failure, venous thromboembolism, pulmonary embolism, and operative complications.

96 myocardial infarction, deep vein thrombosis, pulmonary embolism, and pneumonia).

97 Of these, 3 events-syncope, pulmonary embolism, and serum creatinine increase-in 3 p

98 complications, such as deep vein thrombosis, pulmonary embolism, and stroke.

99 d with pulmonary surgery, those who suffered pulmonary embolism, and those in the IGCCCG poor prognos

100 rs10886430-G in increasing risk for stroke, pulmonary embolism, and venous thromboembolism through i

101 ailure, atrial fibrillation, cardiac arrest, pulmonary embolism, and/or stroke).

102 Deep vein thrombosis (DVT) and pulmonary embolism are collectively known as venous thro

103 ion, stroke, transient ischemic attacks, and pulmonary embolism are major causes of morbidity and mor

104 European estimates of the burden imposed by pulmonary embolism are not available to this date.

105 gns of deep-vein thrombosis, hemoptysis, and pulmonary embolism as the most likely diagnosis) and mea

106 f deep vein thrombosis or non-fatal or fatal pulmonary embolism at 12 months.

107 esence or absence of deep vein thrombosis or pulmonary embolism at the time of IVC filter placement.

108 lment; a secondary end point was symptomatic pulmonary embolism between day 8 and day 90 in the subgr

109 ary arteries done in patients with suspected pulmonary embolisms between March 15 and April 30, 2020

110 erences in D-dimer levels or the location of pulmonary embolisms between the two groups.

111 ism (which includes deep vein thrombosis and pulmonary embolism), but the evidence is uncertain.

112 d hemodynamically stable patients with acute pulmonary embolism can be safely managed as outpatients.

113 Deep venous thrombosis (DVT) and secondary pulmonary embolism cause approximately 100,000 deaths pe

114 Pulmonary embolism caused a four-fold increase in pulmon

115 When pulmonary embolism coexists with a patent foramen ovale,

116 Deep vein thrombosis and pulmonary embolism, collectively defined as venous throm

117 global index" (these end points plus stroke, pulmonary embolism, colorectal cancer, and hip fracture)

118 embolism was 6.4% in those with subsegmental pulmonary embolism compared with 6.0% in those with more

119 uscitation when cardiac arrest was caused by pulmonary embolism compared with hypoxia and primary arr

120 resuscitation from cardiac arrest caused by pulmonary embolism, compared with hypoxia and primary ar

121 rial thromboses and deep-vein thrombosis and pulmonary embolism comprise venous thromboembolism.

122 of symptomatic VTE (deep vein thrombosis and pulmonary embolism, confirmed by duplex ultrasonography

123 , but primary noncardiac conditions, such as pulmonary embolism, critical illness, and sepsis, probab

124 Finally, complications (pulmonary embolism, deep vein thrombosis, acute respirat

125 infarction, stroke, surgical site infection, pulmonary embolism, deep venous thrombosis, and death.

126 wer LOEs were observed for interventions for pulmonary embolism/deep vein thrombosis (A 0%, B 24%, C

127 ter specificity than CT angiography alone in pulmonary embolism detection.

128 anticoagulation within 7 days after injury, pulmonary embolism developed in none of those in the ven

129 In our case, we found both pulmonary embolism due to DVT and paradoxical embolism d

130 entified a group of patients at low risk for pulmonary embolism during follow-up.

131 Deep Vein Thrombosis and pulmonary embolism (DVT/PE) is one of the most common ca

132 overall mortality as a primary endpoint, and pulmonary embolism, fatal pulmonary embolism, and major

133 n a porcine model of acute intermediate-risk pulmonary embolism, fluid loading increased right ventri

134 he device is effective for the prevention of pulmonary embolism for at least 5 weeks after placement

135 sease is associated with a high incidence of pulmonary embolisms, generally peripherally distributed

136 All patients in whom pulmonary embolism had not been ruled out underwent CT p

137 ndary prevention of deep-vein thrombosis and pulmonary embolism has been shown in phase 3 trials.

138 p vein thrombosis (DVT) and its complication pulmonary embolism have high morbidity reducing quality

139 3; 95% CI 0.349-0.783, P = 0.002) and not in pulmonary embolism (HR 0.882; 95% CI 0.511-1.521, P = 0.

140 ndomly assigned to cardiac arrest induced by pulmonary embolism, hypoxia, or primary arrhythmia.

141 Classification of Disease-10 code for acute pulmonary embolism (I26) or any code for deep or superfi

142 Pulmonary surgery, pulmonary embolism, IGCCCG poor prognosis, and smoking i

143 CTPA was positive for pulmonary embolism in 16 of 60 (26.7%).

144 o Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism in 2008 has been lower than expected

145 6.9%), pulmonary infection in 80 (6.5%), and pulmonary embolism in 47 (3.8%) patients.

146 n [3%] in the control group), of which one-a pulmonary embolism in a 64-year-old male patient after 1

147 us thromboembolism, deep vein thrombosis, or pulmonary embolism in adults were included, as were inte

148 We performed a systematic workup for pulmonary embolism in patients admitted to 11 hospitals

149 m clinical outcomes of incidentally detected pulmonary embolism in patients with cancer.

150 Risk factors for pulmonary embolism in patients with coronavirus disease

151 Diagnosis of pulmonary embolism in pregnancy is challenging, with sym

152 inical diagnostic pathways for evaluation of pulmonary embolism in pregnancy that show conflicting re

153 recommended by guidelines for evaluation of pulmonary embolism in pregnancy, reviews current evidenc

154 ded for informed decision making to diagnose pulmonary embolism in pregnancy.

155 ts, and imaging widely used for diagnosis of pulmonary embolism in the non-pregnant population show l

156 little attention to a diagnostic workup for pulmonary embolism in these patients.

157 (2%) patients died from adverse events; one (pulmonary embolism in treatment group A) was possibly re

158 The prevalence of pulmonary embolisms in the same period in 2019 was 13.2%

159 92; 95% confidence interval, 1.80-2.05), and pulmonary embolism (incidence rate ratio, 1.80; 95% conf

160 Pulmonary embolism increased mean pulmonary arterial pre

161 Following approval of rivaroxaban for the pulmonary embolism indication, patients with deep-vein t

162 patients who did not receive a diagnosis of pulmonary embolism initially and did not receive anticoa

163 ective analysis of 143 patients suspected of pulmonary embolism investigated with 3 different scanner

164 .3% of patients, whereas a strategy in which pulmonary embolism is considered to be ruled out with a

165 Pulmonary embolism is incidentally diagnosed in up to 5%

166 Pulmonary embolism is one of the leading causes of mater

167 Pregnancy-associated pulmonary embolism is one of the leading causes of mater

168 Retrospective analyses suggest that pulmonary embolism is ruled out by a d-dimer level of le

169 tic imaging in pregnant women with suspected pulmonary embolism is unknown.

170 ich includes both deep venous thrombosis and pulmonary embolism, is a common and potentially fatal co

171 TE), which includes deep vein thrombosis and pulmonary embolism, is a common complication of cancer a

172 hrombosis (DVT) with its major complication, pulmonary embolism, is a global health problem.

173 y hypertension, a rare complication of acute pulmonary embolism, is characterized by fibrothrombotic

174 iography in the diagnostic approach to acute pulmonary embolism, it has a major role in the evaluatio

175 <1%] on upadacitinib 30 mg), one adjudicated pulmonary embolism (<1%; upadacitinib 15 mg), and one de

176 ells, and suggest that prevention of DVT and pulmonary embolism may be improved by mechanical devices

177 Patients with more life-threatening pulmonary embolism may derive the greatest benefit from

178 n pregnancy is challenging, with symptoms of pulmonary embolism mimicking those of pregnancy.

179 d survival in a collagen/epinephrine-induced pulmonary embolism model of in vivo platelet activation

180 ing during BAT in one [3%] patient each were pulmonary embolism, myocardial infarction, urinary obstr

181 , multiple organ dysfunction syndrome (n=2), pulmonary embolism (n=2), sepsis (n=1), and small intest

182 oside group (death, febrile neutropenia, and pulmonary embolism [n=2 each]; enterocolitis, general ph

183 the deep vein thrombosis network, 12 in the pulmonary embolism network (13 interventions; n=15 555),

184 lactic dose, 28-35 days) ranked first in the pulmonary embolism network (RR 0.02 [95% CrI 0.00-3.86])

185 No pulmonary embolism occurred.

186 Pulmonary embolism often causes cardiac arrest.

187 ere enrolled and evaluated, of whom 7.4% had pulmonary embolism on initial diagnostic testing.

188 Venous thromboembolism (pulmonary embolism or any lower-limb deep-vein thrombosi

189 t result in a lower incidence of symptomatic pulmonary embolism or death at 90 days than no placement

190 ary end point was a composite of symptomatic pulmonary embolism or death from any cause at 90 days af

191 nferior vena cava filter reduces the risk of pulmonary embolism or death in severely injured patients

192 significantly lower incidence of symptomatic pulmonary embolism or death than no placement of a filte

193 current venous thromboembolism manifested as pulmonary embolism or deep vein thrombosis.

194 mbolism was defined as deep vein thrombosis, pulmonary embolism, or both, diagnosed greater than 24 h

195 tic distal or proximal deep-vein thrombosis, pulmonary embolism, or venous thromboembolism-related de

196 us thromboembolism, deep vein thrombosis, or pulmonary embolism outcomes.

197 relevance and optimal therapy for incidental pulmonary embolism, particularly distal clots, is unclea

198 C), pulmonary hypertension (1B), symptomatic pulmonary embolism (PE) (1C), right ventricular (RV) inf

199 on-LR and LRnon-neonates, respectively), and pulmonary embolism (PE) (P < .001; 19.6% and 3.2% in Non

200 nts of follow-up within 1 y in patients with pulmonary embolism (PE) and the factors predictive of co

201 ed all patients who were suspected of having pulmonary embolism (PE) and who underwent CT pulmonary a

202 Medicare fee-for-service beneficiaries with pulmonary embolism (PE) between 1999 and 2015 to assess

203 Asthma and pulmonary embolism (PE) can present with overlapping sym

204 data from the EMR to automatically classify Pulmonary Embolism (PE) cases.

205 While pulmonary embolism (PE) causes approximately 100 000-180

206 ice of the imaging modality for diagnosis of pulmonary embolism (PE) could be influenced by provider,

207 Intermediate-risk (submassive) pulmonary embolism (PE) describes normotensive patients

208 anguage processing (NLP) model in extracting pulmonary embolism (PE) findings from thoracic computed

209 t is not clear whether mortality after acute pulmonary embolism (PE) has decreased over time.

210 d stroke, the treatment and outcome of acute pulmonary embolism (PE) have remained relatively unchang

211 mance of different diagnostic strategies for pulmonary embolism (PE) in patient subgroups is unclear.

212 The prevalence of pulmonary embolism (PE) in patients presenting with sync

213 investigated rates of diagnostic testing for pulmonary embolism (PE) in US emergency departments (EDs

214 Pulmonary embolism (PE) is a leading cause of maternal m

215 Pulmonary embolism (PE) is a potentially fatal cardiopul

216 Pulmonary embolism (PE) is a serious and prevalent cause

217 Acute pulmonary embolism (PE) is associated with high morbidit

218 Pulmonary embolism (PE) is associated with increased ris

219 ong-term effect of thrombolytic treatment of pulmonary embolism (PE) is unknown.

220 Vena cava filter (VCF) placement for pulmonary embolism (PE) prophylaxis in trauma is controv

221 Pulmonary embolism (PE) represents the third leading cau

222 ual-energy CT iodine maps are used to detect pulmonary embolism (PE) with CT angiography but require

223 hich includes deep vein thrombosis (DVT) and pulmonary embolism (PE), is the third most common cause

224 BEC in patients with acute intermediate-risk pulmonary embolism (PE).

225 C) filters are widely used for prevention of pulmonary embolism (PE).

226 phy and may result in proximal thrombosis or pulmonary embolism (PE).

227 caval filters (IVCFs) may prevent recurrent pulmonary embolism (PE).

228 In patients with hemodynamically significant pulmonary embolism, physiological fibrinolysis fails to

229 st prognostication, cardiac arrest caused by pulmonary embolism, postresuscitation oxygenation and ve

230 osite of symptomatic deep-vein thrombosis or pulmonary embolism, progression or recurrence of superfi

231 terms of symptomatic deep-vein thrombosis or pulmonary embolism, progression or recurrence of superfi

232 A contrast material-enhanced CT angiography pulmonary embolism protocol and cardiac MRI were perform

233 A contrast material-enhanced CT angiography pulmonary embolism protocol and cardiac MRI were perform

234 , we assessed patients with acute submassive pulmonary embolism randomly assigned to 1 of 4 tPA dosin

235 Complications of CRT include pulmonary embolism, recurrent deep venous thrombosis, lo

236 between 2013 and 2015, an average of 38 929 pulmonary embolism-related deaths occurred annually in t

237 Deaths were considered pulmonary embolism-related if International Classificati

238 We aimed to assess pulmonary embolism-related mortality and time trends in

239 The observed decreasing trends in pulmonary embolism-related mortality might reflect impro

240 tween 2000 and 2015, age-standardised annual pulmonary embolism-related mortality rates decreased lin

241 ons (nonfatal myocardial infarction, stroke, pulmonary embolism, renal failure, or bowel infarction)

242 myocardial infarction, ischemic stroke, and pulmonary embolism, represent an important source of adv

243 prognostic and therapeutic plan is through a Pulmonary Embolism Response Team, which combines experti

244 In patients with pulmonary embolism, right ventricular dysfunction is ass

245 In patients with cancer with incidental pulmonary embolism, risk of recurrent venous thromboembo

246 Patients in control groups had more pulmonary embolism (RR 2.22, 95% CrI 1.78-2.89, p<0.0001

247 Patients with subsegmental pulmonary embolism seemed to have a risk of recurrent ve

248 mechanical ventilation, respiratory failure, pulmonary embolism, sepsis, or death.

249 -causality grade 3 and 4 adverse events were pulmonary embolism (seven [3%]), prolonged electrocardio

250 Pulmonary embolism still imposes a relevant medical and

251 defibrillator, acute myocardial infarction, pulmonary embolism, stroke/transient ischemic attack, in

252 mpared with 6.0% in those with more proximal pulmonary embolism (subdistribution hazard ratio, 1.1; 9

253 oximal deep-vein thrombosis in a lower limb, pulmonary embolism, symptomatic deep-vein thrombosis in

254 r and fewer had active cancer or concomitant pulmonary embolism than those in the standard anticoagul

255 To evaluate the frequency of acute pulmonary embolism, the use of clinical probability scor

256 five [6%]), febrile neutropenia (five [6%]), pulmonary embolism (three [4%]), bronchitis (two [2%]),

257 (Pulmonary Embolism Thrombolysis study [PEITHO]; NCT00639

258 The PEITHO (Pulmonary Embolism Thrombolysis) trial was a randomized

259 ental acute proximal deep-vein thrombosis or pulmonary embolism to receive oral apixaban (at a dose o

260 r System and Activase for Treatment of Acute Pulmonary Embolism) to identify clinical characteristics

261 ated thrombophlebitis, deep vein thrombosis, pulmonary embolism, transitory ischemic attacks to arter

262 ion (two of eight), diarrhea (two of eight), pulmonary embolism (two of eight), pulmonary hypertensio

263 imer test, all pregnant women with suspected pulmonary embolism undergo computed tomographic (CT) pul

264 Risk stratification for acute pulmonary embolism using imaging presence of right ventr

265 be reasonably explained by a combination of pulmonary embolism, ventilation-perfusion mismatching in

266 2019 mechanically ventilated patients have a pulmonary embolism visible on CT pulmonary angiography.

267 In the entire cohort, the prevalence of pulmonary embolism was 17.3% (95% confidence interval, 1

268 The frequency of acute pulmonary embolism was 23.0% and the Wells Score was exp

269 We performed a prospective study in which pulmonary embolism was considered to be ruled out withou

270 Pulmonary embolism was diagnosed in 20 patients (4.0%) a

271 A pulmonary embolism was found in three patients (23.1%).

272 Pulmonary embolism was identified in 45 of the 355 patie

273 Among the remaining 230 patients, pulmonary embolism was identified in 97 (42.2%).

274 Pulmonary embolism was identified in nearly one of every

275 Survival after pulmonary embolism was increased in diabetic DKO mice re

276 Acute pulmonary embolism was induced by administration of thre

277 Pulmonary embolism was induced by jugular vein infusion

278 Acute pulmonary embolism was induced by large emboli made from

279 If pulmonary embolism was not diagnosed, patients did not r

280 Pulmonary embolism was ruled out if none of the three cr

281 A diagnosis of pulmonary embolism was ruled out in 330 of the 560 patie

282 The diagnosis of pulmonary embolism was ruled out in patients who had a l

283 Pulmonary embolism was safely ruled out by the pregnancy

284 omboembolism was not suspected before death; pulmonary embolism was the direct cause of death in 4 pa

285 The prevalence of pulmonary embolisms was higher in patients with COVID-19

286 tudy involving pregnant women with suspected pulmonary embolism, we assessed three criteria from the

287 ts with deep-vein thrombosis and concomitant pulmonary embolism were also eligible; however, those wi

288 vival following collagen/epinephrine-induced pulmonary embolism were also observed in Dicer1-deficien

289 ch risk factors for deep vein thrombosis and pulmonary embolism were assessed.

290 cancer and a recent diagnosis of incidental pulmonary embolism were eligible.

291 ts with massive (n=31) or submassive (n=119) pulmonary embolism were enrolled.

292 also eligible; however, those with isolated pulmonary embolism were not included.

293 r ischemia) and VTE (deep vein thrombosis or pulmonary embolism) were assessed.

294 th cancer or with intermediate- to high-risk pulmonary embolism, were underrepresented in the Phase I

295 milar results for all endpoints except fatal pulmonary embolism, where evidence of an effect was weak

296 d rhythm analysis: 32 mm (95% CI, 29-36) for pulmonary embolism which was significantly larger than b

297 Thirteen patients (33%) were diagnosed of pulmonary embolism, which was bilateral in six patients

298 ous thromboembolism (deep vein thrombosis or pulmonary embolism) who were new users of apixaban or ri

299 I endometrial cancer with tamoxifen and one pulmonary embolism with placebo.

300 ic deep-vein thrombosis or acute symptomatic pulmonary embolism (with or without deep-vein thrombosis